TY  - JOUR
AU  - Hidalgo-Tenorio, Carmen
AU  - Cortés, Luis López
AU  - Gutiérrez, Alicia
AU  - Santos, Jesús
AU  - Omar, Mohamed
AU  - Gálvez, Carmen
AU  - Sequera, Sergio
AU  - Jesús, Samantha Eisabeth De
AU  - Téllez, Franciso
AU  - Fernández, Elisa
AU  - García, Coral
AU  - Pasquau, Juan
PY  - 2019
DO  - 10.1097/MD.0000000000016813
UR  - http://hdl.handle.net/10668/14378
T2  - Medicine
AB  - Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness...
LA  - en
KW  - Adult
KW  - Anti-HIV Agents
KW  - CD4 Lymphocyte Count
KW  - Cost-Benefit Analysis
KW  - Drug Therapy, Combination
KW  - Economics, Pharmaceutical
KW  - Fees, Pharmaceutical
KW  - Female
KW  - HIV Infections
KW  - HIV-1
KW  - Heterocyclic Compounds, 3-Ring
KW  - Humans
KW  - Lamivudine
KW  - Male
KW  - Middle Aged
KW  - Oxazines
KW  - Piperazines
KW  - Pyridones
KW  - Retrospective Studies
KW  - Viral Load
TI  - DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
TY  - research article
VL  - 98
ER  -